464 related articles for article (PubMed ID: 30902619)
1. Novel proteomic changes in brain mitochondria provide insights into mitochondrial dysfunction in mouse models of Huntington's disease.
Agrawal S; Fox JH
Mitochondrion; 2019 Jul; 47():318-329. PubMed ID: 30902619
[TBL] [Abstract][Full Text] [Related]
2. Oxidative metabolism in YAC128 mouse model of Huntington's disease.
Hamilton J; Pellman JJ; Brustovetsky T; Harris RA; Brustovetsky N
Hum Mol Genet; 2015 Sep; 24(17):4862-78. PubMed ID: 26041817
[TBL] [Abstract][Full Text] [Related]
3. Mutant huntingtin inhibits the mitochondrial unfolded protein response by impairing ABCB10 mRNA stability.
Fu Z; Liu F; Liu C; Jin B; Jiang Y; Tang M; Qi X; Guo X
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1428-1435. PubMed ID: 30802639
[TBL] [Abstract][Full Text] [Related]
4. Brain mitochondrial iron accumulates in Huntington's disease, mediates mitochondrial dysfunction, and can be removed pharmacologically.
Agrawal S; Fox J; Thyagarajan B; Fox JH
Free Radic Biol Med; 2018 May; 120():317-329. PubMed ID: 29625173
[TBL] [Abstract][Full Text] [Related]
5. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease.
Joshi AU; Ebert AE; Haileselassie B; Mochly-Rosen D
J Mol Cell Cardiol; 2019 Feb; 127():125-133. PubMed ID: 30550751
[TBL] [Abstract][Full Text] [Related]
6. Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease.
Berggren KL; Chen J; Fox J; Miller J; Dodds L; Dugas B; Vargas L; Lothian A; McAllum E; Volitakis I; Roberts B; Bush AI; Fox JH
Redox Biol; 2015; 4():363-74. PubMed ID: 25703232
[TBL] [Abstract][Full Text] [Related]
7. Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington's disease.
Li E; Park HR; Hong CP; Kim Y; Choi J; Lee S; Park HJ; Lee B; Kim TA; Kim SJ; Kim HS; Song J
Cell Prolif; 2020 Oct; 53(10):e12893. PubMed ID: 32865873
[TBL] [Abstract][Full Text] [Related]
8. Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.
Choudhury KR; Das S; Bhattacharyya NP
J Proteomics; 2016 Jan; 132():155-66. PubMed ID: 26581643
[TBL] [Abstract][Full Text] [Related]
9. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.
Shirendeb U; Reddy AP; Manczak M; Calkins MJ; Mao P; Tagle DA; Reddy PH
Hum Mol Genet; 2011 Apr; 20(7):1438-55. PubMed ID: 21257639
[TBL] [Abstract][Full Text] [Related]
10. Oxidative metabolism and Ca
Hamilton J; Brustovetsky T; Brustovetsky N
Neurochem Int; 2017 Oct; 109():24-33. PubMed ID: 28062223
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice.
Oliveira JM; Jekabsons MB; Chen S; Lin A; Rego AC; Gonçalves J; Ellerby LM; Nicholls DG
J Neurochem; 2007 Apr; 101(1):241-9. PubMed ID: 17394466
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
13. Proteomic changes in the brains of Huntington's disease mouse models reflect pathology and implicate mitochondrial changes.
Deschepper M; Hoogendoorn B; Brooks S; Dunnett SB; Jones L
Brain Res Bull; 2012 Jun; 88(2-3):210-22. PubMed ID: 21272615
[TBL] [Abstract][Full Text] [Related]
14. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
15. Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice.
Dickson E; Soylu-Kucharz R; Petersén Å; Björkqvist M
Mol Metab; 2022 Mar; 57():101439. PubMed ID: 35007790
[TBL] [Abstract][Full Text] [Related]
16. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
17. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
[TBL] [Abstract][Full Text] [Related]
18. Protein changes in synaptosomes of Huntington's disease knock-in mice are dependent on age and brain region.
Sapp E; Seeley C; Iuliano M; Weisman E; Vodicka P; DiFiglia M; Kegel-Gleason KB
Neurobiol Dis; 2020 Jul; 141():104950. PubMed ID: 32439598
[TBL] [Abstract][Full Text] [Related]
19. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.
Naia L; Cunha-Oliveira T; Rodrigues J; Rosenstock TR; Oliveira A; Ribeiro M; Carmo C; Oliveira-Sousa SI; Duarte AI; Hayden MR; Rego AC
J Neurosci; 2017 Mar; 37(10):2776-2794. PubMed ID: 28123081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
